Easier choices to uplift, support, and empower.

FreeStyle Libre 2 system is indicated for use in people with diabetes age 4 and older. FreeStyle Libre 2 Plus sensor is indicated for use in people with diabetes age 2 and older.

Medicare and other payor criteria may apply. Abbott provides this information as a courtesy and does not guarantee payment or coverage.

The product images are for illustrative purposes only.

* The FreeStyle Libre system apps are only compatible with certain mobile devices and operating systems. Please check our website for more information about device compatibility before using the app. Use of the FreeStyle Libre system apps may require registration with Libreview.

† Study was performed with the outside US version of the FreeStyle Libre 14 day system. Data is applicable to FreeStyle Libre 2 system, as feature sets are similar as FreeStyle Libre 14 day system, excluding alarms.

‡ or ♢ Eligible patients will receive one (1) FreeStyle Libre 2 system sensor or (1) FreeStyle Libre 3 system sensor for users with a compatible mobile phone operating system at $0 copay. The expiration date of the voucher is 60 days from the issue date. This program is available for patients with Type 1 diabetes or Type 2 diabetes or gestational diabetes. Patients ages 18 and older are eligible to sign up and receive an offer for the (1) FreeStyle Libre 2 system sensor or (1) FreeStyle Libre 3 system sensor. Patients ages 4-17 are eligible to receive an offer for the (1) FreeStyle Libre 2 sensor or (1) FreeStyle Libre 3 sensor through their parent or guardian. Patients ages 2-17 are eligible to receive an offer for the (1) FreeStyle Libre 2 Plus sensor or (1) FreeStyle Libre 3 Plus sensor through their parent or guardian. This offer is void where prohibited by law. Abbott may modify or rescind this offer at any time without notice. The discounts are not available to beneficiaries of Kaiser Permanente, Medicare, Medicaid or other federal or state healthcare programs, residents of Massachusetts, or US territories (other than Puerto Rico). The free (1) FreeStyle Libre 2 system sensor or (1) FreeStyle Libre 3 system sensor is provided as a sample and is limited to one sample per eligible person per product identification number. The FreeStyle Libre 2 system sensor or FreeStyle Libre 3 system sensor cannot be re-sold, traded nor submitted to any third-party payer for reimbursement and is not provided as any inducement for future purchases. The free sample card is not health insurance.

§ Fingersticks are required if your glucose alarms and readings do not match symptoms or when you see Check Blood Glucose symbol during the first twelve hours.

†† 60-minute warm-up required when starting the sensor.

‡‡ Based on prescription claims for the aggregate of patients covered by Commercial insurance, Managed Medicare, Managed Medicaid using the FreeStyle Libre personal CGM systems versus competitors’ CGM systems. Does not include fee-for-service Medicare, fee-for-service Medicaid, and uninsured patients. The actual amount a patient pays may vary. The FreeStyle Libre systems require a prescription.

§§ Notifications will only be received when alarm settings are enabled and turned on and the sensor is within 20 feet unobstructed of the reading device.

IIII Silent mode allows users to silence their signal loss and glucose alarms, including urgent low glucose alarm for up to six hours. You will not hear your glucose and signal loss alarms even if you've turned on Override Do Not Disturb but may still get the visual and vibratory notifications based on your phone's settings.

¶¶ To get the Urgent Low Glucose Alarm on your phone with the FreeStyle Libre 2 app, you will first need to start your FreeStyle Libre 2 sensor with your phone. If you do not start your FreeStyle Libre 2 sensor with your phone, you will not get the Urgent Low Glucose Alarm on your phone.

## Based on patient applied sensors currently on the market in the US.

References: 1. Fokkert, Marion, et al. "Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4)." BMJ Open Diabetes Research and Care 7 (2019): e000809. https://doi.org/10.1136/bmjdrc-2019-000809. 2. Haak, Thomas, et al. "Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-treated Type 2 Diabetes: a Multicentre, Open-label Randomised Controlled Trial." Diabetes Therapy 8, no. 1 (2017): 55-73. https://doi.org/10.1007/s13300-016-0223-6. 3. Campbell, Fiona M., et al. "Outcomes of Using Flash Glucose Monitoring technology by Children and young people with Type 1 Diabetes in a Single Arm Study." Pediatric Diabetes 19, no. 7 (2018): 1294-1301. https://doi.org/10.1111/pedi.12735. 4. Data on file. Abbott Diabetes Care, Inc.

ADC-14838 v16.0